57
Participants
Start Date
January 31, 2008
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2011
Bevacizumab
15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
Everolimus
10 mg by mouth daily
Consultants in Medical Oncology and Hematology, Drexel Hill
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
Northeast Georgia Medical Center, Gainesville
Florida Hospital Cancer Institute, Orlando
Gulfcoast Oncology Associates, St. Petersburg
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology & Hematology Associates, Chattanooga
Oncology Hematology Associates of SW Indiana, Evansville
Grand Rapids Clinical Oncology Program, Grand Rapids
St. Louis Cancer Care, Chesterfield
Methodist Cancer Center, Omaha
South Texas Oncology and Hematology, San Antonio
Collaborators (2)
Genentech, Inc.
INDUSTRY
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER